Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00603915
Other study ID # NPC-774
Secondary ID NPC-774
Status Completed
Phase Phase 2
First received
Last updated
Start date June 2006
Est. completion date April 2011

Study information

Verified date February 2019
Source University Health Network, Toronto
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cisplatin or Carboplatin will be given on day 1 every 21 days for 6 cycles; Gemcitabine will be given on day 1 and day 8 every 21 days for 6 cycles. Those patients that do not progress on GC after 6 cycles of chemotherapy will be started on erlotinib daily until disease progression. A cycle of erlotinib will be 28 days. Patients who progress on GC will be offered erlotinib as well,in order to evaluate its activity as a single-agent in the second-line setting.

Patients previously treated with GC have reported a progression-free survival (PFS) of 9 months. We would anticipate an extension of PFS to 12 months in patients treated with GC followed by maintenance erlotinib. Furthermore, we hypothesize that patients who achieved benefit from GC therapy would have further response when treated with maintenance erlotinib, such that this strategy may increase the likelihood of attaining long-term survival.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date April 2011
Est. primary completion date December 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients must have histologically confirmed World Health Organization (WHO) type I (keratinizing squamous cell carcinoma) or WHO type II a or b (differentiated non-keratinizing carcinoma or undifferentiated carcinoma) NPC.

- Presence of clinically and/or radiologically documented disease. At least one site of disease must be unidimensionally measurable as follows:

- X-ray, physical exam > 20 mm

- Spiral CT scan > 10 mm

- Non-spiral CT scan > 20 mm

- Investigations including chest x-ray or CT scan of chest, CT or MRI of head and neck (for patients with locally advanced or locally recurrent disease) and other scans as necessary to document all sites of study disease have been performed within 28 days prior to randomization. (Exceptions will be made only for patients who have negative examinations within 35 days prior to registration; exceptions for bone scans will be made for negative examinations within 60 days prior to registration.)

- Age > 18 years.

- ECOG performance status of 0,1 or 2 (see Appendix II).

- Patients must have a life expectancy of at least 12 weeks.

- Previous Therapy:

- Chemotherapy: Advanced Disease: Patients may not have had prior therapy for recurrent or metastatic disease.

- Curative Therapy: Patients may have had prior chemotherapy (including cisplatin/ carboplatin based regimens) in the neoadjuvant, concurrent and adjuvant setting for locally advanced nasopharyngeal carcinoma provided that 4 weeks have elapsed since treatment and any residual treatment related neuropathy or ototoxicity is < grade 1 for cisplatin dosing on this trial. Patient with neuropathy or ototoxicity > grade 2 will be dosed with carboplatin if otherwise eligible for this trial.

- Radiation: Patients may have received prior radiotherapy provided that the last fraction was given at least 4 weeks prior to registration and all toxicities have resolved. If radiotherapy was delivered to the only site of measurable disease, then progression must have been documented in that site after completion of radiotherapy and prior to registration.

- Previous Surgery: Previous major surgery is permitted provided that it has been at least 21 days prior to patient registration and that wound healing has occurred.

- Laboratory Requirements (must be done within 7 days prior to registration)

- Hematology:

- granulocytes (AGC) > 1.5 x 109/L

- platelets > 100 x 109/L

- Chemistry:

- AST < 2.5 x UNL

- ALT < 2.5 x UNL

- Creatinine clearance(*) : CrCl > 60mls/min for cisplatin or CrCl between 30 - 59ml/min for Carboplatin

(*) calculated

- Patient consent must be obtained according to local Institutional and/or University Human Experimentation Committee requirements. The patient must sign the consent form prior to randomization or registration.

- Patients must be accessible for treatment and follow up.

- Normal serum calcium

Exclusion Criteria:

- Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for > 5 years.

- Patients with non-measurable disease only. (Please note that bone metastases are considered non-measurable).

- Pregnant or lactating women. However, if the patient is of childbearing potential, a urine ß-HCG must be proved negative within 7 days prior to registration. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation.

- Patients with known brain metastases. (A head CT is not necessary to rule out brain metastases, unless there is clinical suspicion of CNS involvement).

- Serious illness or medical condition, which would not permit the patient to be managed according to the protocol including, but not limited to:

- History of significant neurologic or psychiatric disorder which would impair the ability to obtain consent or limit compliance with study requirements;

- Active uncontrolled infection;

- Symptomatic congestive heart failure, unstable angina, cardiac arrhythmia.

- Prior anti-EGFR monoclonal antibody or tyrosine kinase inhibitors.

- Any inflammatory changes of the surface of the eye.

- Hypersensitivity to erlotinib (Tarceva) or to any of the excipients

- Concomitant requirement for medications classified as CYP3A4 inducer or inhibitor. Inhibitors of CYP3A4 are prohibited beginning at least seven (7) days prior to the administration of the first dose of study medication and for the duration of the study. Inducers of CYP3A4 are prohibited beginning at least fourteen (14) days prior to the administration of the first dose of study medication and for the duration of the study.

Study Design


Intervention

Drug:
Gemcitabine
1000mg/m^2 intravenous (IV) day 1 and day 8
Carboplatin/Cisplatin
Area under curve (AUC)=5 (Carboplatin) or 70mg/m^2 (Cisplatin) intravenous (IV) day 1
erlotinib
150mg daily (post GC therapy)

Locations

Country Name City State
Canada Princess Margaret Hospital Toronto Ontario

Sponsors (2)

Lead Sponsor Collaborator
University Health Network, Toronto Hoffmann-La Roche

Country where clinical trial is conducted

Canada, 

References & Publications (1)

You B, Le Tourneau C, Chen EX, Wang L, Jarvi A, Bharadwaj RR, Kamel-Reid S, Perez-Ordonez B, Mann V, Siu LL. A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metast — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Progression Free Survival. From randomization to the first documented disease progression or death from any cause, whichever came first, assessed until all participants randomized to the study have progressed for died. From the on-study date until the date of first documented progression or date of death from any cause any cause until all participants have progressed or died.
Secondary Number of Participants With the Responses Outlined Complete Response (CR): disappearance of all clinical and radiological evidence of tumour.
Partial Response (PR): at least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference the baseline sum LD.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Progressive Disease (PD): at least a 20% increase in the sum of LD of measured lesions taking as references the smallest sum LD recorded since the treatment started. Appearance of new lesions will also constitute progressive disease.
Measured every 2 cycles until the participant is off treatment.
See also
  Status Clinical Trial Phase
Completed NCT00370890 - A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy Phase 3
Recruiting NCT04340024 - Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
Completed NCT00697619 - To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer Phase 2
Completed NCT00078546 - EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC) Phase 1
Recruiting NCT04453826 - Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma Phase 3
Active, not recruiting NCT01074021 - Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Phase 3
Active, not recruiting NCT03890185 - Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC Phase 2
Not yet recruiting NCT04158414 - Applying PET/MR in Oncology - a Prospective Project N/A
Completed NCT02608073 - A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer Phase 2
Completed NCT03656250 - Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI
Recruiting NCT02012699 - Integrated Cancer Repository for Cancer Research
Recruiting NCT04476641 - A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors Phase 2
Terminated NCT03144661 - An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Phase 1
Not yet recruiting NCT06414577 - Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy Phase 2
Recruiting NCT03003182 - A Study of Nasopharyngeal Carcinoma From Guangdong N/A
Not yet recruiting NCT06349889 - Adebrelimab and Chemoradiotherapy in High-risk Locoregionally Advanced Nasopharyngeal Carcinoma Phase 2
Completed NCT01094405 - Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy Phase 2
Not yet recruiting NCT05305131 - Phase II Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer Phase 2
Completed NCT01800071 - A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma Phase 1
Recruiting NCT00304694 - Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients N/A